CoverageForm 410-K10-Q8-K13D13G13F

GEHC Ge Healthcare Technologies Inc. - 8-K

Filed Mar 17, 2026. See issuer overview · financials · original on SEC.gov ↗
Accession
0001932393-26-000013
5.027.019.01

Item 5.02 - Departure/Election of Directors or Certain Officers

267 words

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 13, 2026, the Board of Directors (the “Board”) of GE HealthCare Technologies Inc. (the “Company”) appointed Kevin A. Lobo to serve as a director of the Company, effective immediately. Mr. Lobo’s term will expire at the Company’s 2026 Annual Meeting of Stockholders. The Board also appointed Mr. Lobo as a member of the Talent, Culture, and Compensation Committee of the Board, effective immediately.

Mr. Lobo will receive compensation in accordance with the Company’s compensation program for non-employee directors, which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 10, 2025. The Company will also enter into an indemnification agreement with Mr. Lobo. The form of indemnification agreement is included as Exhibit 10.3 to the Company’s Annual Report on Form 10-K filed with the SEC on February 4, 2026.

There is no arrangement or understanding between Mr. Lobo and any other person pursuant to which he was selected as a director. There are no transactions between Mr. Lobo and the Company that would be reportable under Item 404(a) of Regulation S-K.

Also on March 13, 2026, each of Risa Lavizzo-Mourey and Tomislav Mihaljevic informed the Board that they would not stand for re-election to the Board at the Company’s 2026 Annual Meeting of Stockholders due to other commitments. Neither Dr. Lavizzo-Mourey’s nor Dr. Mihaljevic’s decision was a result of any disagreement on a matter related to the Company’s operations, policies, or practices.

Item 7.01 - Regulation FD Disclosure

116 words

Item 7.01 Regulation FD Disclosure.

On March 17, 2026, the Company issued a press release announcing the appointment of Kevin A. Lobo to its Board. A copy of the press release is furnished as Exhibit 99.

The information furnished pursuant to Item 7.01, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 - Financial Statements and Exhibits

37 words

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Description

99

Press Release of GE HealthCare Technologies Inc., dated March 17, 2026.

104

The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.